Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Evidence of a urogenital gonococcal infection (prior culture, NAAT test, Gram stain, sexual contact)~2. Willing to abstain from anal, oral, or vaginal sexual intercourse or use condoms until study completion.~3. Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test at enrollment.~Exclusion Criteria:~1. Confirmed, or suspected, complicated or systemic gonococcal infections such as pelvic inflammatory disease, arthritis, or endocarditis.~2. Known HIV, chronic hepatitis B, or hepatitis C infection.~3. Known concomitant infection which would require additional systemic antibiotics.~4. Use of systemic or intravaginal antibiotics within 30 days prior to study drug administration.~5. Current use of corticosteroid drugs or other immunosuppressive therapy.~6. Cytotoxic chemotherapy or radiation therapy within the previous 3 months.~7. Known significant renal, hepatic, or hematologic impairment.~8. History of intolerance or hypersensitivity to macrolide antibiotics.~9. Any concomitant condition that, in the opinion of the Investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy and follow-up could be completed (e.g., life expectancy \<30 days).

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solithromycin (CEM-101) (Type: EXPERIMENTAL): A single oral dose of 1200 mg solithromycin
- Solithromycin 1000 mg (Type: EXPERIMENTAL): A single oral dose of 1000 mg solithromycin

Based on this trial design, predict the completion outcome and termination type (if applicable).